AN2 THERAPEUTICS INC ANTX
COM · Common Stock · CUSIP 037326105
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersMenlo Park, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 19.4m as of 2022-05-06, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $14.98.
Biggest buyers
| RA CAPITAL MANAGEMENT, L.P. | New | +3.7m |
| BVF INC/IL | New | +1.6m |
| CITADEL ADVISORS LLC | New | +1.4m |
| Avidity Partners Management LP | New | +688.3k |
| DEERFIELD MANAGEMENT COMPANY, L.P. | New | +584.1k |
| Monashee Investment Management LLC | New | +433.3k |
| Woodline Partners LP | New | +150.0k |
| VANGUARD GROUP INC | New | +74.7k |
| MILLENNIUM MANAGEMENT LLC | New | +74.2k |
| COWEN AND COMPANY, LLC | New | +60.3k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Commodore Capital LP 13G · passive investor new · filed 2026-03-16 | 9.9% |
| Coastlands Capital Partners LP 13G · institution new · filed 2025-06-04 | 9.3% |
| Vivo Opportunity Fund Holdings, L.P. 13G · passive investor new · filed 2026-03-13 | 8.0% |
| Easom Eric 13G · exempt (held before listing) +1.7 pts · filed 2026-02-13 | 7.9% |
| Adjuvant Global Health Technology Fund, L.P. 13G · exempt (held before listing) filed 2025-02-28 | 7.9% |
| INTEGRATED CORE STRATEGIES (US) LLC 13G · passive investor new · filed 2026-03-13 | 6.3% |
Fell to 5% or below in the last year: Almitas Capital LLC (4.1%, 2026-05-15)
Insider purchases and sales in Q1 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q2 2020 | 0 | — | 0 | — | — |
| Q3 2020 | 0 | — | 0 | — | — |
| Q4 2020 | 0 | — | 0 | — | — |
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 0 | — | 0 | — | — |
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 2 | $4.8m | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2022-03-29 | RA Capital Healthcare Fund LP +4 10% owner · See Footnotes | Bought | $25.0m1.7m shares |
| 2022-03-29 | Aziz Kabeer Director · By Adjuvant Global Health Technology Fund, L.P. | Bought | $2.5m166.7k shares |
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. +1 10% owner · By Adjuvant Global Health Technology Fund, L.P. | Bought | $2.5m166.7k shares |
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. +3 10% owner | Bought | $2.5m166.7k shares |
| 2022-03-29 | Readnour Robin Shane Director · See footnotes | Bought | $2.3m153.3k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q1 2022
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. 1.21% of their portfolio | 3.7m $55.3m | New |
| BVF INC/IL 0.97% of their portfolio | 1.6m $24.4m | New |
| CITADEL ADVISORS LLC 0.02% of their portfolio | 1.4m $20.6m | New |
| Avidity Partners Management LP 0.23% of their portfolio | 688.3k $10.4m | New |
| DEERFIELD MANAGEMENT COMPANY, L.P. 0.20% of their portfolio | 584.1k $8.8m | New |
| Monashee Investment Management LLC 1.89% of their portfolio | 433.3k $6.5m | New |
| Woodline Partners LP 0.04% of their portfolio | 150.0k $2.3m | New |
| Alyeska Investment Group, L.P. 0.02% of their portfolio | 125.0k $1.9m | Not comparable |
| VANGUARD GROUP INC 0.00% of their portfolio | 74.7k $1.1m | New |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 74.2k $1.1m | New |
| COWEN AND COMPANY, LLC 0.09% of their portfolio | 60.3k $908.0k | New |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 19.5k $294.0k | New |
| BARCLAYS PLC 0.00% of their portfolio | 18.2k $275.0k | New |
| WELLINGTON MANAGEMENT GROUP LLP 0.00% of their portfolio | 16.6k $250.0k | New |
| Anson Funds Management LP 0.00% of their portfolio | 2.5k $38.0k | New |
| UBS Group AG 0.00% of their portfolio | 1.2k $17.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 885 $14.0k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 653 $10.0k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |